Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 4Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasms 2Vaccinia 1Stomach Neoplasms 1Solid Tumors 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Ovarian Epithelial 1Breast Diseases 1

Interventions

Everolimus 15surufatinib 7lutetium Lu 177 dotatate 6lanreotide 6amino-acid, glucose, and electrolyte solution 5Octreotide 5Sunitinib 4Data Collection 4pasireotide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3tislelizumab 2pembrolizumab 2fosbretabulin 2arginyllysine 2Temozolomide 2Paclitaxel 2PM 01183 2Irinotecan 2Carboplatin 264Cu-SARTATE 23-Iodobenzylguanidine 2toripalimab 1telotristat ethyl 1taxane 1repotrectinib 1pralsetinib 1pelcitoclax 1liposomal doxorubicin 1gadoteridol 1gadoterate meglumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroendocrine Tumors × taxane × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡